  Refractory pityriasis rubra pilaris ( PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis , most commonly tumor necrosis<symptom> factor ( TNF) Î± antagonists and ustekinumab; however , the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.